NCT03140722TERMINATEDanonymous

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Indication / condition

AI-normalized

Anemia

Intervention

Source record

vadadustat, epoetin alfa

Related intelligence directories

Indication directory: Anemia Modality directory: small molecule Target directory: Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Source & freshness

Source record

NCT ID

NCT03140722

Original source

ClinicalTrials.gov

Source last updated

Feb 21, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03140722

Title

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Sponsor

Akebia Therapeutics

Status

TERMINATED

Phase

Phase 2

Condition raw

Anemia

Condition normalized

Anemia

Modality raw

Anemia

Modality normalized

small molecule

Target raw

Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Target normalized

Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Interventions

vadadustat, epoetin alfa

Public preview

Source record

The trial evaluated vadadustat, an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor, against epoetin alfa for treating anemia in patients with DD-CKD who are hyporesponsive to erythropoiesis stimulating agents. The study was terminated due to a revised study design after enrolling only 2 participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

Investment-Ready Snapshot

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Source & freshness

Public preview

Create an account to unlock this report

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Investment-Ready Snapshot

Provenance

Protocol Description

Outcome Measures

Eligibility

Known Results And Readout Context

Patent And IP Landscape

Contacts